Over-testing Galactomannan in patients with hematological malignancies: A retrospective analysis from a tertiary care university hospital in Türkiye.

This study aimed to evaluate the Galactomannan (GM) correlation with radiologic findings, treatment decisions and financial impact of over-testing. In this cohort, GM testing yielded a low diagnostic return, requiring 53 tests to obtain one positive result and 103 tests to identify a probable invasive aspergillosis (IA) case, generating a considerable avoidable financial burden. These findings highlight the need to rationalize GM utilization and align testing with IA risk to reduce hospital costs.